

Revision Required [BaliMedJ] [Manuscript ID: 4636]

8 messages

Editor Bali Medical Journal <editorbalimedicaljournal@gmail.com> To: putunitacahyawati@gmail.com Sun, Jul 9, 2023 at 6:35 AM

Dear Authors,

Thank you for submitting your article entitled: "Simvastatin: a new therapeutic strategy for Chronic Kidney Disease (CKD)".

Based on our author guidelines, Your article fulfilled the minimal required structure, https://www.balimedicaljournal.org/index.php/bmj/pages/view/authorguidlines In order to have a better-structured article, we suggest you edit based on a checklist, the simplest way, you may use the Publons review checklist.

According to the new International regulation, please fulfill the requirements below:

1. Ethical clearance number/<u>statement</u> (author statement) and/or informed consent at the end of the manuscript (**Confirmed**).

2. Please state your conflict of interest in the paper. (Confirmed)

- 3. Please state the funding (if any) in your paper. (**Confirmed**)
- 4. Please state each author's contribution. (Confirmed)

5. Why does the author provide a 5.2, 10.4, and 20.8 mg/kgBW dosage of Simvastatin in this study? Are there any preliminary studies regarding this dosage used by authors? Please clarify your answer in the methods section.

6. How many observers are involved in evaluating the fibrosis area fraction in this study to minimize the measurement bias? In addition, how does the author make sure that there is no interobserver bias in evaluating the fibrosis area to validate the results? Please elaborate your answer in the methods section.

7. How does the author evaluate the serum creatinine levels in this study? Please provide thorough protocols regarding the preanalytical specimen collection until reporting the findings.

8. What is the limitation of this study? In addition, what are the best suggestions for the further-future studies regarding those study limitations mentioned by authors? Please elaborate it further at the end of the discussion section.

Please revise your article with the missing details, and send it back to us in 7 days (July 16th, 2023).

In addition, I do need to remind you that Bali Medical Journal is free to submit and Open Access for our readers. However, if your manuscript is accepted for publication, as the author, you will be charged **1,500 USD for APC (not included proofreading).**

We encourage all authors to submit a narrative abstract video of the manuscript. A special waiver of 250 USD is given to all authors who submit their narrative abstract video throughout 2023 (<u>https://www.balimedicaljournal.org/index.php/bmj/pages/view/journalinfo</u>). Narrative abstract video must be conducted in a brightly lit room, wearing a neat shirt with a collar. Any institutional or university attributes should be used.

Please **confirm** if you agree with this information.

Thank you for trusting us with your hard work

Warm regards,

Editorial Board Member

Bali Medical Journal (BaliMedJ) P-ISSN: 2089-1180 E-ISSN 2302-2914 Indexed at: Web of Science (WOS) Clarivate Analytics SCOPUS Elsevier All Indexing Organisation



Editor Bali Medical Journal <editorbalimedicaljournal@gmail.com> To: putunitacahyawati@gmail.com Wed, Jul 12, 2023 at 2:31 PM

[REMINDER]

Dear Authors,

Thank you for submitting your article entitled: "Simvastatin: a new therapeutic strategy for Chronic Kidney Disease (CKD)".

Based on our author guidelines, Your article fulfilled the minimal required structure, https://www.balimedicaljournal.org/index.php/bmj/pages/view/authorguidlines In order to have a better-structured article, we suggest you edit based on a checklist, the simplest way, you may use the Publons review checklist.

According to the new International regulation, please fulfill the requirements below:

1. Ethical clearance number/<u>statement</u> (author statement) and/or informed consent at the end of the manuscript (**Confirmed**).

2. Please state your conflict of interest in the paper. (Confirmed)

3. Please state the funding (if any) in your paper. (**Confirmed**)

4. Please state each author's contribution. (**Confirmed**)

5. Why does the author provide a 5.2, 10.4, and 20.8 mg/kgBW dosage of Simvastatin in this study? Are there any preliminary studies regarding this dosage used by authors? Please clarify your answer in the methods section.
6. How many observers are involved in evaluating the fibrosis area fraction in this study to minimize the measurement bias? In addition, how does the author make sure that there is no interobserver bias in evaluating the fibrosis area to validate the results? Please elaborate your answer in the methods section.

7. How does the author evaluate the serum creatinine levels in this study? Please provide thorough protocols regarding the preanalytical specimen collection until reporting the findings.

8. What is the limitation of this study? In addition, what are the best suggestions for the further-future studies regarding those study limitations mentioned by authors? Please elaborate it further at the end of the discussion section.

Please revise your article with the missing details, and send it back to us in 7 days (July 16th, 2023).

In addition, I do need to remind you that Bali Medical Journal is free to submit and Open Access for our readers. However, if your manuscript is accepted for publication, as the author, you will be charged **1,500 USD for APC (not included proofreading).**

We encourage all authors to submit a narrative abstract video of the manuscript. A special waiver of 250 USD is given to all authors who submit their narrative abstract video throughout 2023 (<u>https://www.balimedicaljournal.org/index.php/bmj/pages/view/journalinfo</u>). Narrative abstract video must be conducted in a brightly lit room, wearing a neat shirt with a collar. Any institutional or university attributes should be used.

Please **confirm** if you agree with this information.

Thank you for trusting us with your hard work

Warm regards,

Editorial Board Member
[Quoted text hidden]

nita cahyawati <putunitacahyawati@gmail.com> To: Editor Bali Medical Journal <editorbalimedicaljournal@gmail.com>

Dear editors of BMJ

I have revised my manuscript based on suggestions sent by the editor. I have marked the revisions in yellow to make checking easier.

Thank You

[Quoted text hidden]

dr. Putu Nita Cahyawati, M.Sc Department of Pharmacology and Pharmacy Faculty of Medicine and Health Sciences Warmadewa University JI. Terompong No.24 Denpasar, Bali 0361 240727

BMJ inggris (revisi).docx 3429K

Editor Bali Medical Journal <editorbalimedicaljournal@gmail.com> To: nita cahyawati <putunitacahyawati@gmail.com> Fri, Jul 14, 2023 at 6:18 AM

Dear Authors,

We would like to inform you that the revised version of the manuscript has been well received and forward to the peerreviewers. A further suggestion from peer-reviewers is very important to consider the final decision of the manuscript being accepted/rejected by the editorial boards. Please wait for further information regarding the publication.

Best regards

Editorial Board Member [Quoted text hidden]

Editor Bali Medical Journal <editorbalimedicaljournal@gmail.com> To: nita cahyawati <putunitacahyawati@gmail.com> Sat, Jul 15, 2023 at 5:56 AM

Dear Authors,

We would like to inform you that the revised version of the manuscript entitled "Simvastatin: a new therapeutic strategy for Chronic Kidney Disease (CKD) [Manuscript ID: 4636]" has been well received.

Final Decision: Accepted with minor revision

The article publishing charge is now payable before the paper can be progressed any further and an invoice is accessible here (Attachment) (Valid until: July 22nd, 2023).

The acceptance of your paper is subject to all outstanding content-related queries being addressed to the satisfaction of the Publisher.

If you have any questions about your paper please contact us at any time, we welcome your feedback.

Yours sincerely

Editorial Board Member

[Quoted text hidden]

4636-Invoice BMJ-Putu Nita Cahyawati.pdf 843K

putunitacahyawati <putunitacahyawati@gmail.com> To: Editor Bali Medical Journal <editorbalimedicaljournal@gmail.com> Sat, Jul 15, 2023 at 8:21 AM

Dear BMJ editors

I attach my payment proof according the invoice that I receive.

Best regards Nita

Dikirim dari Galaxy saya

------ Pesan asli ------Dari: Editor Bali Medical Journal <editorbalimedicaljournal@gmail.com> Tanggal: 15/07/23 05.57 (GMT+08:00) Ke: nita cahyawati <putunitacahyawati@gmail.com> Subjek: Re: Revision Required [BaliMedJ] [Manuscript ID: 4636]

[Quoted text hidden]

BNI		
	aked Reethandi	
Itare Relening Tujuan	1270-KOLORI	
Nama Penetima	INTIGARI SAINS MEDIS PT	
Tanggal Transaksi	18-07/2025	
Waktu Transokol	07:00:36 W B	MBRC_1689379239479.png
Email Penerima	publicationset@gmail.com	148K
Bank Tujuan	101	1401
Nama Pengirim	PUTUNERCARNAVAD	
Nominal	20.402.001	
Teo	0	
Intal	35,400,885	
Reterangen	Pembagaran Jumal 0H0	

Editor Bali Medical Journal <editorbalimedicaljournal@gmail.com> To: putunitacahyawati <putunitacahyawati@gmail.com>

Sat, Jul 15, 2023 at 9:08 AM

Dear Authors,

We have received your payment and we would like to inform you that your manuscript is now currently being processed by our reviewer and editor. Please patiently wait until we send you the revised version of your manuscript.

Thank you for trusting us with your hard works.

Best regards

Editorial Team [Quoted text hidden]

Editor Bali Medical Journal <editorbalimedicaljournal@gmail.com> To: putunitacahyawati <putunitacahyawati@gmail.com> Wed, Jul 19, 2023 at 6:21 AM

Letter of Acceptance

Dear: Putu Nita Cahyawati^{1*}, I Nyoman Mantik Astawa², Bagus Komang Satriyasa³, I Made Bakta⁴

¹Department of Pharmacology and Pharmacy, Faculty of Medicine and Health Sciences, Universitas Warmadewa, Denpasar, Bali, Indonesia

²Department of Animal Disease, Faculty of Veterinary Medicine, Universitas Udayana, Denpasar, Bali, Indonesia

³Department of Pharmacology and Therapy, Faculty of Medicine, Universitas Udayana, Denpasar, Bali, Indonesia

⁴Department of Internal Medicine, Faculty of Medicine, Universitas Udayana, Denpasar Bali, Indonesia *Corresponding author: putunitacahyawati@gmail.com

I am very excited to accept your paper entitled:

"Simvastatin: a new therapeutic strategy for Chronic Kidney Disease (CKD)."

Your paper will be published in the issue of Vol. 12 Number 2, 2023. http://dx.doi.org/10.15562/bmj.v12i2.4636

(Online Link: http://balimedicaljournal.org/index.php/bmj/article/view/4636).

And it usually takes 2 to 4 months for your journal to show up at Google Scholar, but if you need it fast, you may add it up manually using your google scholar account. The CrossRef and DOI number usually activate in 3 until 6 months.

Bali Medical Journal is indexed in Web of Sciences, Scopus, and many other indexing organization: http://balimedicaljournal.org/index.php/bmj/pages/view/indexing.

Please do not hesitate to contact us if you need anything. It has been a pleasure for us to proofread and edit your work, and we are looking forward to your colleagues and your other papers in the near future. [Quoted text hidden]

1497 Letter of Acceptance 4636 Putu Nita Cahyawati.pdf 658K